NCT03561584View on ClinicalTrials.gov

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

September 1, 2024

Study Completion Date

November 1, 2024

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Sulfasalazine

Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.

DRUG

Placebo

Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.

Trial Locations (1)

02467

RECRUITING

Brigham and Women's Hospital, Chestnut Hill

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER